# Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

> **NCT04311671** · PHASE3 · COMPLETED · sponsor: **Medicines Development for Global Health** · enrollment: 12979 (actual)

## Conditions studied

- Onchocerciasis

## Interventions

- **DRUG:** Moxidectin
- **DRUG:** Ivermectin
- **DRUG:** Albendazole

## Key facts

- **NCT ID:** NCT04311671
- **Lead sponsor:** Medicines Development for Global Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 12979 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311671, "Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04311671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*